Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Sep 27, 2014; 6(9): 677-684
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.677
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.677
Table 2 Steatosis prevalence and distribution in the different groups
| Steatosis prevalence | Steatosisgrade 1 | Steatosisgrade 2-3 | |
| HBV-HCV group (n = 66) | 47.0% | 43.6% | 3.4% |
| HBV group (n = 66) | 33.3% | 21.2% | 12.1% |
| HCV group (n = 198) | 49.5% | 23.2% | 26.3%a |
- Citation: Zampino R, Coppola N, Cirillo G, Boemio A, Minichini C, Marrone A, Stanzione M, Starace M, Durante-Mangoni E, Sagnelli E, Restivo L, Salzillo G, Fascione MC, Nevola R, Giudice EMD, Adinolfi LE. Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. World J Hepatol 2014; 6(9): 677-684
- URL: https://www.wjgnet.com/1948-5182/full/v6/i9/677.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i9.677